Fundamentals of personalised medicine in the treatment of breast and ovarian cancer

Anna Doraczyńska-Kowalik¹, ², Gabriela Janus-Szymańska¹, ², Rafał Matkowski², ³, Katarzyna Gabalewicz², Dagmara Michałowska², Maria M. Sąsiadek¹

¹Department of Genetics, Wroclaw Medical University, Wroclaw, Poland
²University Medical Centre, Wrocław, Poland
³Department of Oncology, Wrocław University School of Medicine, Wrocław, Poland

Individualisation of medical management based on prognostic and predictive markers (personalised medicine) allows customisation of prophylaxis and optimisation of treatment by increasing its efficiency and minimisation of adverse effects. In the case of breast cancer, therapy selection is still based on histopathology and immunohistochemical assessment including analysis of estrogen receptor (ER) expression, progesterone receptor (PgR) expression and over-expression or amplification of receptor tyrosine kinase erbB-2 gene (ERBB2 aka HER2). An additional role, facilitating decision on application or waiver of chemotherapy in early breast cancer, may be played by panels assessing gene expression within tDNA (tumour DNA, i.e. DNA isolated from tumour cells) and evaluation of concentration of uPA (urokinase-type plasminogen activator) and PAI-1 (plasminogen activator inhibitor type 1) in tumour cells. Growing hope surrounds the new, targeted therapies, including: inhibitors of CDK 4/6 (cyclin-dependant kinases 4 and 6), mTOR inhibitors (rapamycin’s mammalian target), inhibitors of poly(ADP-ribose)polymerase(PARP) or inhibitors of PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinases). For ovarian cancer, treatment selection is based on assessment of the histopathologic type, malignancy degree, FIGO classification and platinum sensitivity of the tumour. However, the increasing use of PARP inhibitors and angiogenesis inhibitors is noteworthy. In the context of personalised medicine for both these cancers, an important element involves also individualisation of prophylactic and therapeutic recommendations in carriers of germline mutations associated with hereditary cancer syndromes.

Key words: personalised medicine, breast cancer, ovarian cancer, predictive tests, prognostic tests, germline mutations

Introduction to personalised medicine

Personalised therapies are currently among the most notable trends in medicine, especially in management of cancer patients. Progress in genetics and molecular pathology allowed selection of a number of biomarkers of patient-specific status. Their analysis enables selection of an optimal, individually tailored procedure. The said biomarkers can be diagnostic (helpful in precise diagnosis), prognostic (allowing estimation of the probable course of the disease in terms of recurrence risk), and predictive (allowing prediction of the likely response to particular therapies, and therefore helpful in selecting personalised therapy). Normally, biological material from the tumour is used for marker evaluation which may be carried out at the level of genetic changes (using appropriately se-
lected cytogenetic and/or molecular tests) as well as protein changes (usually using immunohistochemical methods). The concept of personalised medicine in oncology is very broadly defined and it includes choosing patient-specific treatment, taking into account both individual prophylaxis and the type, time and sequence of therapy, as well as doses of drugs used. Management adapted to the needs of an individual patient is aimed at increasing the effectiveness of prophylaxis and therapy and at reducing the frequency and intensity of side effects [1].

The following review presents basics of personalised medicine as applied in breast cancer and ovarian cancer patients, considering especially guidelines of the European Society for Medical Oncology (ESMO).

Genetic profile of breast and ovarian cancer
The basis of the neoplastic transformation process lies in mutations. Their accumulation leads to genetic instability within neoplastic cells.

Most cancers, including most breast cancers (70–75%) and most ovarian cancers (75–90%) are sporadic in nature and develop as a consequence of accumulated somatic mutations, which are non-hereditary changes acquired during the individual's life and limited to the genome of neoplasm's cells. Presence of somatic mutations is thus limited to tDNA – DNA isolated from tumour cells. Characteristically, sporadic neoplasms are usually diagnosed in older age patients with no family history of cancer.

Some cancers, including 15–20% of breast cancers, are familial. In these cases, their origin is characterised by aggregation of neoplasms of a specific type among members of a family. In patients with familial neoplasms, multi-gene variations are observed in constitutive genome, which increase susceptibility to environmental cancerogenic factors. Therefore, familial neoplasms develop as a consequence of combined effect of constitutive genetic susceptibility and adverse environmental factors, which together lead to occurrence of mutations related to neoplastic transformation. However, the complexity and limited penetrance of constitutional variants do not allow their application as markers that would unequivocally define the individual risk of developing a cancer.

Hereditary neoplasms (developing on the basis of inherited mutation) are relatively rare e.g. hereditary breast cancer accounts for 5–10% of all breast cancer cases, and hereditary ovarian cancer for 10–25% of all ovarian cancer cases. They are characterised by unique clinical features. A suspicion of a hereditary cancer should be raised with such clinical features as: atypical cancer, young age of diagnosis (e.g. pre-menopausal breast cancer), multifocal and/or bilateral lesions, occurrence of two or more primary neoplasms in an individual or occurrence of neoplasms of the same spectrum in several members of a family. In patients with hereditary breast and/or ovarian cancer, observations confirmed an increased lifetime risk of development of not only those cancers, but also other neoplasms of the spectrum characteristic of the syndrome in question. A hereditary cancer is associated with carrying a specific germline mutation, i.e. a hereditary, congenital mutation of a single gene which is present in all cells of the body, and therefore identified both in tDNA tests and on DNA isolated from cells outside the tumour (e.g. peripheral blood lymphocytes, saliva cells, oral mucosa cells, fibroblasts). Identifying people with hereditary breast and/or ovarian cancer is important not only because of the individualisation of prophylactic and therapeutic recommendations for such patients, but also considering the necessity to provide genetic counselling to other family members [1].

Breast cancer – individualisation of therapy based on histological and immunohistochemical classification
Selection of treatment for patients with breast cancer is still based on histopathology and immunochemistry of the tumour.

Decisions concerning targeted therapy are mostly based on the tumour's biological profile. In the case of breast cancer, this profile refers to the immunohistochemical (IHC) analysis of expression of the estrogen receptor (ER), expression of the progesterone receptor (PgR) and overexpression of the human epidermal growth factor type 2 receptor (HER2) or (if this assessment is equivocal) analysis of amplification of receptor tyrosine kinase erbB-2 aka HER2 receptor gene (ERBB2 aka HER2). The above biomarkers are diagnostic, prognostic and predictive, too (tab. I).

According to ESMO recommendations, examination of HER2 status should conform to standards of the American Society of Clinical Oncology – College of American Pathologists (ASCO-CAP). Additionally, amplification of HER2 gene may be analysed by in situ hybridisation (ISH) or fluorescence in situ hybridisation (FISH), usually applied as an additional test in cases of equivocal immunochemistry results (+2) [2].

Each patient with an invasive breast cancer should have ER, PgR and HER2 status assessed, optimally in the biopsy specimen [2, 3]. In cases of equivocal or triple negative receptor status of the biopsy specimen, additionally post-operative material should be immunohistochemically tested. Furthermore, HER2 status should be re-evaluated in post-operative material in cases in which a test of the biopsy specimen revealed G1 ER+, PgR+, HER2+ NST breast cancer, as well as for selected cases of specific-type breast cancer. In all of the above situations, the postoperative results should be considered final [2]. ESMO also recommends that in cases of advanced breast cancer in the metastatic stage, at least one IHC assessment on biological material from a metastatic focus should be performed to assess the biological profile, which may be different from that of the primary tumour [4].
Breast cancer – therapy individualisation based on molecular changes and ancillary markers

**PI3K inhibitors**
A lot of hope is now associated with PI3K inhibitors (inhibitors of phosphatidylinositol-4,5-bisphosphate 3-kinases), such as alpelisib, which are new targeted therapeutical substances applied in the next-line treatment (after hormonal anti-estrogen therapy) in patients with advanced ER-positive, HER2-negative breast cancer displaying presence of PIK3CA gene mutation (catalytic subunit of alpha-phosphatidylinositol-4,5-bisphosphate 3-kinase) in tDNA. In these cases, it is recommended to use the PI3K inhibitor in combination with fulvestrant [5]. Importantly, in tDNA of luminal breast cancers, mutation of PIK3CA gene is the most frequent molecular lesion, so a large group of women with luminal breast cancer would benefit from application of the targeted therapy using PI3K inhibitors [5, 6].

**PARP inhibitors**
The latest ESMO recommendations suggest also possibility to apply PARP inhibitors (poly (ADP-ribose) polymerase – PARP) – olaparib or talazoparib – in the next-line treatment (after anthracycline and taxanes) in patients with germline BRCA1 or BRCA2 mutation in cases of advanced breast cancer.

**Table I.** Individualisation of systemic treatment of breast cancer depending on the tumour’s biological profile

| Classification | ER | PgR | HER-2 | Prognosis            | Systemic treatment [2-6]                                                                 |
|----------------|----|-----|-------|----------------------|-----------------------------------------------------------------------------------------|
| luminal A      | +  | +   | –     | **good**             | 1. Hormone therapy 5–10 years: • estrogen receptor blockers like tamoxifen, toremifene and/or • aromatase inhibitors like anastrozole, letrozole, exemestane. 2. Chemotherapy in cases of T3 and/or involvement of 4 lymph nodes. 3. CDK 4/6 inhibitors (palbociclib, ribociclib, abemaciclib) or mTOR inhibitors (everolimus) in cases of advanced cancer. 4. PI3K inhibitors (alpelisib) with fulvestrant in the next line of treatment (after hormone therapy) in patients with advanced breast cancer and PIK3CA mutation in tDNA. 5. PARP inhibitors (olaparib or talazaparib) in the next line of treatment (after anthracycline and taxanes) in patients with a germline BRCA1 or BRCA2 mutation in cases of advanced cancer. |
| luminal B      | +  | –   | –     | **moderate**         |                                                                                          |
| HER2-negative  |     |     |       |                      | 1. Hormone therapy 5–10 years: • estrogen receptor blockers like tamoxifen, toremifene and/or • aromatase inhibitors like anastrozole, letrozole, exemestane. 2. Chemotherapy. 3. Anti-HER2 therapy in HER2-positive cases: • monoclonal antibodies such as trastuzumab, pertuzumab, T-DM1 and/or • kinase inhibitors such as lapatinib, neratinib, tucatinib. 4. CDK 4/6 inhibitors (palbociclib, ribociclib, abemaciclib) or mTOR inhibitors (everolimus) in cases of advanced HER2-negative luminal B cancer. 5. PI3K inhibitors (alpelisib) with fulvestrant in the next line of treatment (after hormone therapy) in patients with advanced HER2-negative luminal B breast cancer and PIK3CA mutation in tDNA. 6. PARP inhibitors (olaparib or talazaparib) in the next line of treatment (after anthracycline and taxanes) in patients with a germline BRCA1 or BRCA2 mutation in cases of HER2-negative advanced cancer. |
| luminal B      | +  | +/- | +     | **moderately good**  |                                                                                          |
| HER2-positive  |     |     |       |                      |                                                                                          |
| non-luminal    | –  | –   | +     | **moderately severe**| 1. Anti-HER2 therapy in HER2 positive cases: • monoclonal antibodies such as trastuzumab, pertuzumab, T-DM1 and/or • kinase inhibitors such as lapatinib, neratinib, tucatinib. 2. Chemotherapy. |
| HER2-negative  |     |     |       |                      |                                                                                          |
| triple negative | – | –  | –     | **severe**           | 1. Chemotherapy (considering platinum derivatives, among others). 2. PARP inhibitors (olaparib or talazaparib) in the next line of treatment (after anthracycline and taxanes) in patients with a germline BRCA1 or BRCA2 mutation in cases of advanced cancer. |

**Gene expression panels**
In the targeted therapy of breast cancer, gene expression panels on tDNA can be applied, too: MammaPrint (Agenda, Amsterdam, The Netherlands), Oncotype DX (Genomic Health, Redwood City, CA, USA). Prosigna (PAM 50, NanoString Technologies, Seattle, WA, USA), Endopredict (Myriad Genetics SaltLake City, UT, USA), Breast Cancer Index (Biotheranostics, Inc., San Diego, CA, USA). The above tests assess expression of selected – usually several dozen – genes related to processes of proliferation, angiogenesis, metastasis and others, allowing determination of the specific expression profile of the tumour. According to the ESMO recommendations, gene expression panels are used as a supplementary prognostic marker (enabling estimation of the course of the neoplastic disease and the risk of metastasis) and a predictive marker mainly in cases of early ER-positive and HER2-negative breast cancer, without
nodal involvement or with involvement of up to 3 lymph nodes. In such cases, results of the discussed panels play an auxiliary role in equivocal situations, where application or withdrawal of chemotherapy is considered [2, 3].

**Assessment of uPA and PAI-1 concentrations in tumour cells**

Tests to assess uPA (urokinase-type plasminogen activator) and PAI-1 (plasminogen activator inhibitor-1) concentrations in tumour cells have similar application in individualisation of breast cancer therapy as gene expression panels. The test is based on the ELISA technique, and it requires a fresh and unfixed or freshly frozen tumour specimen. According to ESMO recommendations, the test should be considered primarily in cases of early breast cancer without lymph node involvement. High concentrations of uPA and/or PAI-1 are considered unfavourable prognostic markers suggesting high risk of recurrence and indicating that adjuvant chemotherapy is advisable [2, 3].

**Broad-panel tDNA molecular testing**

Next generation sequencing (NGS) allows analysis of the whole exome (whole-exome sequencing – WES) or even the whole genome (whole genome sequencing – WGS) of the tumour, raising hopes for application of new targeted therapies. Broad-panel molecular tests showed that the most frequent molecular changes in cancer cells include gene mutations in PIK3CA, TPS3, PTEN, AKT1, CDH1, ARID1B, CASP8, BRCA1, RB1, MLL3, MAP3K1, MAP3K13, NCO1, SMARC1D1, CDKN1B, TBX3, RNUX1, CBFB, AFF2, PIK3R1, PTPN22, PTPRD, NF1, SF3B1 and CCND3, as well as copy number variants (CNV) in PIK3CA, ERBB2, TP53, MAP2K4, MLL3, CDKN2A, PTEN and RB1 [6]. Comprehensive genomic profiling (CGP) enables establishment of a molecular classification of breast cancers based on changes in individual signalling pathways, such as PI3K / AKT / mTOR pathway (molecular target for such therapeutic substances as everolimus, temsirolimus, alpelisib), double-strand DNA break repair in genes BRCA1 / BRCA2 / PALB2 (their mutations are a good predictive factor for PARP inhibitors), estrogen receptor ER pathway, cell cycle regulatory pathway CCND1 / CDK4 / RB1 (molecular target for palbociclib, ribociclib, abemaciclib), growth factors ERBB2 / EGFR / FGFR1 (molecular target for such therapeutic substances as trastuzumab, pertuzumab, afatinib, lapatinib, neratinib, pazopanib, ponatinib) [7]. Thus, detection of changes in the cellular pathways identified in breast cancer allows assumptions concerning potential efficacy of therapies targeted at them. There are commercial broad-panel genetic tests available on the market, offering sequencing of many genes within tDNA, both in the form of WES and WGS tests of the tumour genome, as well as gene panels selected for a given tumour. Their analysis is potentially important in the context of developing targeted therapies. However, ESMO recommendations do not provide for routine application of broad-panel molecular tests of tDNA, due to their currently limited use in clinical practice in patients with breast cancer.

**Hereditary breast cancer**

There is a specific dimension of personalised medicine applied in breast cancer which concerns carriers of mutations typical for hereditary cancer syndromes including breast cancer. Breast cancer appears in the spectrum of many hereditary cancer syndromes caused by germline mutations of such genes as: BRCA1 and BRCA2 (HBOC hereditary breast and ovarian cancer), CHEK2, PALB2, TP53 (Li-Fraumeni syndrome), ATM, PTEN (Cowden syndrome), CDH1 (hereditary diffuse gastric cancer) or STK11 (Peutz-Jeghers syndrome). The role of mutations of individual genes in aetiology of the hereditary breast cancer varies depending on the studied ethnic group, but most hereditary breast cancers are associated with germline mutation of BRCA1 or BRCA2 gene responsible for the hereditary breast and ovarian cancer syndrome [8, 9].

Currently in Poland, module I of the National Cancer Control Programme of the Ministry of Health (Narodowy Program Zwalczania Chorób Nowotworowych Ministerstwa Zdrowia – NPZChN MZ) recommends for all breast cancer patients genetic counselling. Genetic testing to assess critical hereditary mutation is recommended for selected group of patients, in whom the hereditary form of disease has been suspected on the basis of pedigree analysis. The recommendations concern the presence of five germline mutations of BRCA1 gene which are the most common in the Polish population (c.5266dupC, c.181T>G, c.4035del, c.66_67AG, c.3695_3699GTAAA), two selected germline mutations of PALB2 gene (c.509_510del, c.168_171TTGT) and three selected germline mutations of CHEK2 gene (c.1100del, del5395, c.4444+1G>A) . This range of molecular diagnostics has been developed based on the specificity of the Polish population, with dominating carriers of one of the five founder mutations of BRCA1 gene, which account for aetiology of approximately 64% of BRCA-dependent hereditary breast cancers [10].

In cases of hereditary history (tab. II) module I of the NPZChN MZ Programme recommends expanded molecular diagnostics, including sequencing of BRCA1 and BRCA2 genes, currently by the next generation sequencing (NGS) technique. However, this test, too, has some limitations. It is not recommended for analysing large rearrangements (deletions and duplications), which account for up to 10% of mutations identified in BRCA1 and BRCA2 genes [11]. Their occurrence should be verified by another method such as MLPA technique (multiplex ligation-dependent probe amplification). Furthermore, sequencing entire gene-coding sequences yields a lot of information requiring diligent bio-IT analysis for verification of clinical significance of the identified variations. Identifying variations is a complex process, requiring advanced in silico analysis, assessment of the variation’s frequency in the general population, access to available databases, such as: ClinVar, dbSNP, Breast
Cancer Information Core, Varsome, 1000GP, Consensus PathDB, Gene Ontology, GWAS, OMIM, UniProt or HGMD, etc. The currently applied classification recommended by the American College of Medical Genetics and Genomics (ACMG) provides for five classes of pathogenic effect of variations:

• non-pathogenic variant (class 1),
• possibly non-pathogenic variant (class 2),
• variant of unknown clinical significance (VUS, class 3),
• possibly pathogenic variant (class 4),
• pathogenic variant (class 5) [12].

Class 4 and Class 5 variations are considered to be mutations, i.e. changes of clinical significance. The analysis of germline VUS variants remains a major challenge in genetic counselling. Therefore, it is recommended that prophylactic and therapeutic recommendations should be based on history and clinical analysis. Further – considering progress of knowledge on molecular changes and constant updating of databases – it is stressed that the identified variation should be consulted again after 2–3 years.

The variability of clinical significance of individual variations within a studied gene can be observed in the case of CHEK2 gene: its shortened protein or frameshift variants have a far more significant impact on neoplasm risk than missens variations. Therefore, individual medical recommendations should be based not only on the gene where the mutation is found, but also on the type of change identified.

Identification of a germline mutation is a molecular confirmation of a specific hereditary cancer syndrome. However, due to the limitations of genetic testing presented above, non-detection of mutations in the tested range does not allow for clear exclusion of the suspected hereditary cancer syndrome. The result of a genetic test should therefore be supported by specialised genetic counselling, and individual medical recommendations should take into account not only results of molecular tests, but also clinical and history evaluation.

Patients with family and clinical history suggestive of hereditary form of disease who do not have mutations revealed in sequencing of BRCA1 and BRCA2 remain a challenge. Hereditary breast and ovarian cancer (HBOC), while dominant, is not the only syndrome of hereditary predisposition to cancers with breast cancer in the spectrum. In some of the other, rarer syndromes, there are associated characteristic signs and symptoms, such as specific family history, macrocephaly (Cowden syndrome) or typical changes in skin and mucosa (Peutz-Jeghers syndrome), facilitating identification of a specific suspicion and referring to targeted genetic testing. In non-specific cases, the only option is to consider broad-panel genetic NGS testing, which allows sequencing of many genes associated with many hereditary cancer syndromes within a single test. There are many commercial wide-panel tests available on the market, differing in the scope of the studied genes. They may take into account both genes of high penetrance (in the case of occurrence of a germline mutation, they increase the risk of developing neoplasms from a given spectrum very strongly, even fivefold) and of moderate penetrance (increasing the risk of developing neoplasms from a given spectrum about 2–5 times in the case of occurrence of a germline mutation).

Carriers of germline mutations should be informed about the risk of occurrence of the mutation in their relatives. Genetic counselling should cover not only people with hereditary breast cancer, but also selected members of their families. Individualisation of medical procedures applies to all mutation carriers (including those diagnosed with another cancer from the spectrum of a given cancer syndrome, as well as those without cancer diagnosis), and also families with cancer in which no causative mutation was detected.

Detailed characteristics of the most frequent hereditary cancer syndromes of spectrum including breast cancer, and therapeutic and prophylactic recommendations for mutation carriers considering ESMO guidelines and module I of the NPZCHN Programme are shown in table II.

**Ovarian cancer – classification**

In patients with diagnosed ovarian cancer prognosis of the course of disease and potential response to applied therapy depends on the neoplasm’s histopathology type, tumour grading, four-stage FIGO classification and tumour’s platinum sensitivity.

According to the classification of the World Health Organisation (WHO), epithelial ovarian tumours include:

- serous type (about 80% of cases),
- endometrioid type (about 10% of cases),
- clear-cell type (about 5% of cases),
- mucous type,
- transitional epithelial tumours (Brenner tumour),
- mixed type,
- undifferentiated type,
- unclassified type [20].

Additionally, there is a separate group of borderline epithelial tumours of the ovary, accounting for 10–15% of ovarian tumours and characterised by equivocal histopathology, which doesn’t allow their identification as either malignant or non-malignant ovarian neoplasms. Serous borderline tumours are the most frequent, followed by mucous and endometrioid types [20].

Apart from the standard classification, there is also another division of epithelial ovarian tumours, considering jointly: etiopathogenetic factors, histopathological type, histologic malignancy stage, molecular changes, response to chemotherapy and prognosis. This division distinguishes the following types:

- type 1 ovarian cancer, characterised by low histological malignancy, a more stable course and frequent mutations of KRAS, BRAF, ERBB2, PTEN, PIK3CA and ARID1A genes in the genetic material of the tumour (ARID1A mutations are particularly frequently identified in cases of endometrioid and clear cell carcinoma). Type 1 ovarian cancer includes low-grade serous, endometrioid, mucous and clear-cell
Table II. Selected hereditary cancer syndromes with breast cancer in the spectrum - characteristics and therapeutic and prophylactic management

| Hereditary cancer syndrome | Genes in which germ-line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|----------------------------|---------------------------------------------|--------------------------------|-----------------------------------------------|-------------------------------------------------|----------------|
| hereditary breast and ovarian cancer (HBOC) [8, 11] | BRCA1 | According to ESMO guidelinesthe following conditions confirm a need for genetic testing: a) a personal history of breast cancer ≤50 years of age or triple negative TNBC breast cancer and/or ovarian cancer; b) a strong family cancer history (first/second/third degree relatives); c) a history of at least three breast cancers among first/third degree relatives regardless of age; d) a personal history of melanoma; e) a personal history of prostate cancer; f) a personal history of other hereditary cancers (e.g., pancreatic cancer, melanoma, colorectal cancer). | - risk of developing breast cancer in carriers up to approx. 87% - risk of developing contralateral breast cancer in carriers up to approx. 83% - risk of developing breast cancer in male carriers up to approx. 1% | - risk of developing ovarian cancer up to approx. 6.3% - risk of developing prostate cancer up to approx. 8.5% - risk of developing pancreatic cancer up to approx. 3% | - each carrier should perform monthly self-palpation of the breasts - each carrier is recommended to breastfeed for a long time and to abandon/limit hormone replacement therapy (HRT) - each carrier is recommended to have a medical palpation of the breasts and breast imaging every 6 months (the age of beginning the tests depends on the family and clinical assessment, but should not be later than 25 years of age): MRI alternating with ultrasound (up to 30 years of age) or mammography (after 30 years of age) - chemoprevention with tamoxifen may be considered in any carrier - each carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction - in carriers who developed breast cancer, breast conserving surgery should be abandoned in favour of mastectomy, possibly with prophylactic contralateral mastectomy, ideally with simultaneous reconstruction - in carriers who have developed triple-negative or luminal type breast cancer that progresses despite anti-estrogen therapy, PARP inhibitors (olaparib or talazaparib) should be considered as the next-line treatment (after anthracycline and taxanes) - each carrier from 30 years of age is recommended to have a TV-USG of the small pelvis and assessment of serum CA125 concentration every 6–12 months - in each carrier, prophylactic bilateral adnexectomy is recommended, optimally at the age of 35–40 years, after completion of procreation plans - carriers diagnosed with ovarian cancer are expected to respond well to platinum derivatives and PARP inhibitors - each male carrier should conduct regular breast self-examination, and from 30–35 years of age annual medical palpation of the breasts is recommended (especially in carriers of the BRCA2 mutation) - each male carrier (especially with BRCA2 mutation) may consider annual screening for prostate cancer starting from 40–45 years of age. |

*BRCA2* | According to module I of the NPZChM MZ Programme 3:

a) analysis of occurrence of five mutation of *BRCA1* gene which are the most common in the Polish population (c.5267dupC, c.181T>G, c.4035del, c.66_67AG, c.3695_3699GTAAA) in:
- any person with a personal history of breast cancer (including DCIS, male breast cancer)
- any person with a history of pancreatic and/or prostate cancer (including peritoneal cancer and fallopian tube cancer)
- any person with ovarian cancer (including peritoneal cancer and fallopian tube cancer)
- in families with breast cancer and ovarian cancer in cases where the person with cancer is unavailable for examination, the analysis should be performed in the closest relatives (optimally first or second degree)

b) sequencing of *BRCA1* and *BRCA2* genes:
- only in people diagnosed with breast and/or ovarian cancer
- only in cases where 5 most common mutations in the Polish population have been excluded
- only if:
  - the patient has both breast cancer and ovarian cancer, including the first diagnosis before the age of 50
  - the patient has had bilateral breast cancer, including the first diagnosis before the age of 50

- risk of developing breast cancer in carriers up to approx. 84%
- risk of developing contralateral breast cancer in carriers up to approx. 62%
- risk of developing breast cancer in male carriers up to approx. 9%
- risk of developing ovarian cancer up to approx. 2.7%
- risk of developing prostate cancer up to approx. 20%
- risk of developing pancreatic cancer up to approx. 7%
- a discreetly increased risk of developing melanoma (of the skin and/or eyeball)
| Hereditary cancer syndrome | Genes in which germ-line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|----------------------------|-----------------------------------------------|-------------------------------|-----------------------------------------------|---------------------------------------------------------------------|-----------------|
| • the patient has been diagnosed with breast cancer or ovarian cancer and has a first and/or second degree relative who was diagnosed with breast and/or ovarian cancer, at least one of these cases before the age of 50 |
| • the patient was diagnosed with breast cancer before the age of 50 or ovarian cancer at any age, and in addition first and/or second degree relatives were diagnosed with male breast cancer and/or ovarian cancer |
| c) in families with identified specific BRCA1/2 mutation, an occurrence of hereditary mutation should be verified in the carrier’s family, above all first-degree relatives |
| d) if a specific BRCA1/2 mutation is identified in DNA from tumour cells (tDNA), its presence should be analysed on DNA isolated from outside the tumour cells (blood, saliva, oral swab, skin biopsy specimen) to assess the nature of the mutation (somatic, i.e. non-hereditary or germline, i.e. hereditary). |
| 2 germ-line mutations of PALB2 [8, 11, 13] | PALB2 | According to module I of the NPZChN MZ Programme: two selected mutations of PALB2 (c.509_510del, c.168_171TTGT) should be analysed: |
| a) in any person with breast cancer |
| b) in the case when the person diagnosed with breast cancer is unavailable for examination and the family has been diagnosed with: |
| – bilateral breast cancer |
| – breast cancer before 40 years of age |
| – male breast cancer |
| – 2 cases of breast cancer and/or ovarian cancer in people who are first/second degree relatives. |
| – risk of developing breast cancer in carriers up to approx. 58% |
| – increased risk of developing pancreatic cancer |
| – increased risk of developing breast cancer in male carriers |
| – in all carriers of the BRCA2 mutation, annual dermatological and ophthalmological testing for melanoma may be considered, especially in the presence of this tumour in relatives |
| – in any carrier of the BRCA2 mutation, especially in cases with a family history of pancreatic cancer, annual pancreatic cancer screening (EUS or MRI) may be considered, starting from the age of 50 or 10 years earlier than the youngest family history of pancreatic cancer |
| 2 germ-line mutations of CHEK2 [8, 11] | CHEK2 | According to module I of the NPZChN MZ Programme: three selected mutations of CHEK2 (c.1100del, del5395, c.444+1G > A) should be analysed: |
| a) in any person with breast cancer |
| b) in the case when the person diagnosed with breast cancer is unavailable for examination and the family has been diagnosed with: |
| – bilateral breast cancer |
| – breast cancer before 40 years of age |
| – male breast cancer |
| – 2 cases of breast cancer and/or ovarian cancer in people who are first/second degree relatives. |
| – risk of developing breast cancer up to approx. 39% |
| – risk of developing prostate cancer |
| – risk of developing papillary thyroid cancer |
| The spectrum and risk of cancer development largely depend on the type of mutation found. Literature data are ambiguous for many CHEK2 variants. |
| – each carrier should perform monthly self-palpation of the breasts |
| – each carrier is recommended to have a medical palpation of the breasts and breast imaging every 6 months (the age of beginning the tests depends on the family and clinical assessment, but should not be later than 20–25 years of age); MRI alternating with ultrasound up to 30 years of age) or mammography (after 30 years of age) |
| – each carrier may consider bilateral prophylactic mastectomy optimally with simultaneous reconstruction, but no such recommendations are included in module I of NPZChN MZ Programme |
| – the person with identified mutation should be notified that if she gets pregnant by a carrier of PALB2 mutation, the risk of giving birth to a child with Fanconi anaemia type N is 25% |
| – each carrier should perform monthly self-palpation of the breasts |
| – each carrier is recommended to have a medical palpation of the breasts and breast imaging every 6 months (the age of beginning the tests depends on the family and clinical assessment, but should not be later than 20–25 years of age); MRI alternating with ultrasound up to 30 years of age) or mammography (after 30 years of age) |
| – no such recommendations are included in module I of NPZChN MZ Programme |
| – module I NPZChN MZ additionally recommends annual ultrasound of the thyroid gland |
| Hereditary cancer syndrome | Genes in which germ line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|-----------------------------|-----------------------------------------------|-------------------------------|-----------------------------------------------|-------------------------------------------------|------------------|
| **Li-Fraumeni Syndrome (LFS)**<sup>[8, 14]</sup> | **TP53** | Sequencing of TP53 gene is recommended if: 1. Chompret criteria are met 2. Diagnosis of breast cancer in a patient aged ≤30 3. Diagnosed malignant neoplasm in LFS spectrum in a patient aged ≤45 and at least one relative in first/second degree with diagnosed malignant neoplasm in LFS spectrum (excluding breast cancer if in the original patient) at the age of ≤55 or in a multifocal form 4. Diagnosed multiple primary malignancies (except multiple primary breast cancer lesions), of which at least 2 belong to the LFS spectrum and the first diagnosis occurred at the age ≤45 5. Diagnosed rare malignant neoplasm typical of LFS, such as: adrenal cortex cancer, choroid plexus cancer, anaplastic embryonal rhabdomyosarcoma 6. The patient was diagnosed with hypodiploid acute lymphoblastic leukemia (ALL) before 21 years of age 7. Findings in tumour cell studies: - presence of TP53 mutation of allele frequency approaching 50% or higher in tDNA - absent or decreased expression of TP53 in IHC tests | - notably young age of oncolgical diagnoses (excluding <18 years of age) and risk of multifocal primary cancers in a single patient - neoplastic disease develops in at least 90% of female carriers and 70% of male carriers of the TP53 mutation - risk of developing a soft tissue sarcoma up to approx. 2.7% - risk of developing osteosarcoma up to approx. 1.6% - risk of developing a malignant tumour of the CNS up to approx. 14% (especially glioblastoma, astrocytoma) - risk of developing adrenal cortex cancer (ACC) up to approx. 1.3% - risk of developing leukaemia (especially ALL, AML, MDS) up to approx. 4% - risk of developing lymphoma up to approx. 2% - risk of developing colorectal cancer (up to approx. 3–8%) and gastric cancer - risk of developing melanoma | - each carrier should perform monthly self-palpation of the breasts - in each carrier from 20 years of age medical palpation of the breasts is recommended every 6–12 months - in each carrier from 20 years of age annual breast MRI is recommended - in carriers who developed breast cancer, breast conserving surgery should be abandoned in favour of mastectomy, possibly with prophylactic contralateral mastectomy, ideally with simultaneous reconstruction - each carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction - in all carriers from 25 years of age gatroesophagoduodenoscopy and colonoscopy is recommended (at least every 5 years, the endoscopic image determines the frequency of the examination) - annual neurological examination is recommended for all carriers and consideration of annual whole-body MRI and six-monthly blood counts - in all carriers, ultrasound of the abdominal cavity and small pelvis may be considered every 3–4 months until the age of 18 and every year after the age of 18 - annual dermatological examination is recommended for all carriers - X-ray and ionizing tests and therapies should be abandoned (or limited) in all carriers |
| **Cowden syndrome**<sup>[8, 15]</sup> | **PTEN** | Performance of PTEN genetic testing is recommended in patients with a Cleveland Clinic score (CC score) of at least 10. The scale considers assessment of occurrence of malignant cancers (including breast, endometrium, thyroid, renal cancer) and non-malignant tumours and non-neoplastic lesions typical for Cowden syndrome spectrum. [https://www.lerner.ccf.org/gmi/ccscore/](https://www.lerner.ccf.org/gmi/ccscore/) | - risk of developing breast cancer in female carriers up to approx. 50%, according to some sources up to approx. 85% - risk of developing thyroid cancer (especially follicular cancer) up to approx. 35% - risk of developing renal cancer (especially papillary cancer) up to approx. 35% - risk of developing endometrial cancer up to approx. 28% - risk of developing colorectal cancer up to approx. 9% - risk of developing melanoma up to approx. 5% - very frequent occurrence on non-malignant tumours | - each carrier should perform monthly self-palpation of the breasts - in each carrier from 20–25 years of age medical palpation of the breasts is recommended every 6–12 months - in each carrier from 30 years of age annual breast MRI and/or mammography is recommended - in each carrier from 30–35 years of age annual TV-USG with endometrial biopsy is recommended (unless a hysterectomy has been previously performed) - each carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction - any carrier may consider prophylactic hysterectomy - in all carriers, annual dermatological control and annual ultrasound of the thyroid gland are recommended |
| Hereditary cancer syndrome | Genes in which germ-line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|---------------------------|---------------------------------------------|-------------------------------|-------------------------------|-------------------------------------------------|----------------|
| Hereditary cancer syndrome | Genes in which germ-line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
| Hereditary cancer syndrome | Genes in which germ-line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
| Hereditary cancer syndrome | Genes in which germ-line mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |

**ATM**
- Risk of developing breast cancer in carriers up to approx. 52%
- Carriers are also likely to have a moderately increased risk of developing gastric and colorectal cancer
- Each carrier should perform monthly self-palpation of the breasts
- Each carrier is recommended to have a medical palpation of the breasts every 6-12 months and annual MRI of the breasts (no clear recommendations as to the age to start the tests, probably no later than 25)
- X-ray and ionizing tests and therapies should be abandoned (or limited) in all carriers
- The person with identified mutation should be notified that if she gets pregnant by a carrier of ATM mutation, the risk of giving birth to a child with ataxia-telangiectasia is 2.9%

**CDH1**
- Risk of developing diffuse gastric cancer up to approx. 42%
- Risk of developing diffuse gastric cancer up to approx. 70% in men and up to approx. 56% in women
- Each carrier should perform monthly self-palpation of the breasts
- In each carrier from 20 years of age medical palpation of the breasts every 6 months is recommended and also regular breast imaging: annual MRI (from 20 years of age) alternating with annual mammography (additionally from 30 years of age)
- Each female carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction
- In each adult male carrier, it is recommended to consider prophylactic gastrectomy, performed optimally between 20 and 30 years of age

**Hereditary diffuse gastric cancer**
- Sequencing with the analysis of rearrangement (deletion / duplication) of CDH1 gene is recommended in the following cases:
  - Diagnosed diffuse gastric cancer at any age and at least one relative in the first/second degree with diagnosed any gastric cancer
  - Diffuse gastric cancer diagnosed in the patient or a relative in the first/second degree before the age of 40
  - The patient or family member has had both diffuse gastric cancer and lobular breast cancer, and at least one diagnosis was made before the age of 50
- Risk of developing lobular breast cancer in carriers up to approx. 42%
- Each carrier should perform monthly self-palpation of the breasts
- In each carrier from 20 years of age medical palpation of the breasts every 6 months is recommended and also regular breast imaging: annual MRI (from 20 years of age) alternating with annual mammography (additionally from 30 years of age)
- Each female carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction
- In each adult male carrier, it is recommended to consider prophylactic gastrectomy, performed optimally between 20 and 30 years of age

**Germline ATM mutations**
- Risk of developing breast cancer in carriers up to approx. 52%
- Carriers are also likely to have a moderately increased risk of developing gastric and colorectal cancer
- Each carrier should perform monthly self-palpation of the breasts
- Each carrier is recommended to have a medical palpation of the breasts every 6-12 months and annual MRI of the breasts (no clear recommendations as to the age to start the tests, probably no later than 25)
- X-ray and ionizing tests and therapies should be abandoned (or limited) in all carriers
- The person with identified mutation should be notified that if she gets pregnant by a carrier of ATM mutation, the risk of giving birth to a child with ataxia-telangiectasia is 2.9%
| Hereditary cancer syndrome | Genes in which germline mutations are present | Indications for genetic testing | Risk of breast cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|-----------------------------|---------------------------------------------|-------------------------------|-----------------------------------------------|-------------------------------------------------|----------------|
| Peutz-Jeghers Syndrome (PJS) [8, 18, 19] | STK11 | Sequencing of STK11 gene is recommended for patients with:  
identifying presence of ≥2 hamartomatous polyps in the GI tract, confirmed by histopathology  
identifying presence of at least 1 hamartomatous polyp of the gastrointestinal tract and the family history indicative of PJS  
identifying presence of at least 1 hamartomatous polyp and presence of dermal and mucosal discoloration spots typical of PJS  
identifying presence of dermal and mucosal discoloration spots typical of PJS and family history suggesting |  
risk of developing breast cancer in carriers up to approx. 54% |  
presence of multiple polyps (usually hamartomatous) of the GI tract  
risk of developing colorectal cancer up to approx. 39%  
risk of developing pancreatic cancer up to 36%  
risk of developing gastric cancer up to approx. 29%  
risk of developing small intestine cancer up to approx. 13%  
risk of development of ovarian tumour–SCTAT (sex cord tumours with annular tubules) up to approx. 2.1%  
risk of developing a malignant cervical adenoma up to approx. 10%  
risk of developing endometrial cancer up to approx. 9%  
risk of developing Sertoli cell tumour of the testicle up to approx. 9%  
risk of developing lung cancer up to approx. 17%  
frequently associated dermal and mucosal discoloration: around lips, eyes, nose and on the oral mucosa, around the penile and on fingers |  
each carrier should perform monthly self-palpation of the breasts  
each carrier from 20–25 years of age medical/palpation of the breasts every 6 months is recommended and also regular breast imaging: annual MRI (from 20–25 years of age) alternating with annual mammography (additionally from 30 years of age)  
each female carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction  
each carrier imaging of the upper GI tract and small intestine (gastroscopy/MR endoscopy/capsule endoscopy) and colonoscopy are recommended at the age of 8 and then:  
every 2–3 years in the case of polypoid lesions identified at the age of 8  
at 18 years of age in the case of no polypoid lesions identified at the age of 8 and then from 18 years of age every 2–3 years  
in girls, ultrasound of the pelvis minor with ovary. Evaluation is recommended from childhood until the age of 12  
in each adult carrier, annual TV-USG examination and annual evaluation of serum CA125 concentration are recommended  
in each carrier from 30 years of age. Annual screening for pancreatic cancer (EUS or MR-MRCP) is recommended  
in boys, annual examination of the testicles (palpation and possibly ultrasound) is recommended from childhood until approx. 12 years of age |
ovarian cancers, malignant Brenner tumours, and borderline epithelial tumours;

- type 2 ovarian cancer, characterised by high histological malignancy, aggressive course and metastatic tendency, poor prognosis and frequent TP53 mutations (very common in high-grade serous ovarian cancer), BRCA1 and BRCA2 mutations (any of the above identified in approximately 20% of type 2 ovarian cancers) in genetic material of the tumour. Type 2 ovarian cancer includes serous or endometrioid high-grade ovarian cancers, mixed-type tumours and undifferentiated tumours. Characteristically, in the most common cases of type 2 ovarian cancers, i.e. serous tumours and those of high histological malignancy, a specific etiopathogenetic mechanism is suggested, with the neoplastic process starting within the hyphae of the fallopian tube [20].

**Ovarian cancer – individualisation of therapy**

**Histopathological classification vs. response to chemotherapy**

The mainstay of treatment in patients with ovarian cancer is radical surgery and adjuvant chemotherapy, usually applying platinum derivatives (carboplatin, cisplatin) in combination with paclitaxel. In further treatment lines, depending on platinum sensitivity of the tumour, it is possible to apply platinum preparations and paclitaxel, traditional or pegylated liposomal doxorubicin (PLD), topotecan, gemcitabine and trabectedin [20].

Predictive markers of response to the classic chemotherapy regimen include histopathological type and degree of malignancy of ovarian cancer. Low effectiveness of standard chemotherapy protocols based on platinum compounds is observed in cases of serous ovarian tumours of low histological malignancy and clear-cell ovarian cancer [20].

**PARP inhibitors**

In systemic treatment of patients with ovarian cancer, poly-(ADP-ribose) polymerase (PARP) inhibitors such as olaparib, niraparib and rucaparib are becoming increasingly important. The effect of these substances relies on inducing double-strand DNA breaks in neoplasm cells, leading to interruption of the cell cycle and death of the cancer cells. Therefore, the best effects of treatment with PARP inhibitors are achieved in the presence of the BRCA1 or BRCA2 mutation in tDNA, because in such tumours DNA break repair is impaired by homologous recombination deficiency (HRD) and dependence of the repair process on the mechanisms related to PARP polymerases. Consequently, routine sequencing of both genes on tDNA isolated from post-operative material, cell block or possibly biopsy specimen has been introduced to the diagnostic process. Until recently, inclusion of PARP inhibitors in ovarian cancer therapy depended on presence of the pathogenic variants (class 5) or probably pathogenic variants (class 4) of BRCA1 or BRCA2 in tDNA.

DNA break repair failure due to homologous recombination deficiency may occur also because of other molecular changes than BRCA1 or BRCA2 mutation and further clinical trials showed that therapeutic effect of application of PARP inhibitors was observed in general in cases of ovarian cancer with evidence of homologous recombination deficiency. There are commercial tests on the market that enable assessment of the homologous gene recombination deficiency and the resulting genomic instability in tumour cells. These tests are based on the measurement of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and damage to chromosomal structure (large scale state transitions – LST), among other parameters. However, the tests are notably expensive. Furthermore, the latest clinical trial results show that PARP inhibitor exhibit efficacy which is also significant, although lower, in the group of patients with ovarian cancer without BRCA1 and BRCA2 mutations in tDNA, and even without evidence of HRD [20].

Current recommendations provide for administration of any PARP inhibitor in patients with recurrent platinum-sensitive ovarian cancer of high grade of malignancy, regardless of mutational status of BRCA1 and BRCA2 in tDNA in the case of supportive treatment after administration of chemotherapy based on platinum compounds, as well as in patients with advanced (FIGO grades III and IV), platinum-sensitive ovarian cancer of high grade of malignancy with known BRCA1 or BRCA2 mutation in tDNA in supportive treatment after administration of chemotherapy based on platinum compounds.

There have also been recommendations concerning consideration of rucaparib monotherapy as next-line treatment in patients with ovarian cancer and known BRCA1/2 mutation in tDNA, who have contraindications to chemotherapy with platinum derivatives [20].

**Inhibitors of angiogenesis**

Enhanced angiogenesis is one of the pathomechanisms leading to increasing mass of ovarian cancer. Therefore, angiogenesis inhibitors such as bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF) are considered in the treatment of ovarian cancer. Current ESMO recommendations provide for application of bevacizumab in first-line treatment along with paclitaxel and carboplatin in patients with advanced ovarian cancer (FIGO stage IV and FIGO stage III after suboptimal cytoreduction with residual lesions exceeding 1 cm) in an adjuvant and supportive scheme for one year and in cases of recurrence in patients with platinum-sensitive ovarian cancer, who have not received bevacizumab as first-line treatment [20].

**Hereditary ovarian cancer**

Personalised medicine in cases of ovarian cancer, similarly to breast cancer, also extends to an individual approach in
| Hereditary cancer syndrome | Genes in which germline mutations are present | Indications for genetic testing | Risk of ovarian cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|---------------------------|---------------------------------------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------|
| Breast and ovarian cancer (HBOC) | BRCA1 | a) genetic testing for HBOC should be considered in families with: | risk of developing ovarian cancer up to approx. 65% | risk of developing breast cancer in carriers up to approx. 8.7% | each carrier from 30 years of age is recommended to have a TV-USG of the small pelvis and assessment of serum CA125 concentration every 6–12 months |
| | | - ovarian cancer | | - risk of developing breast cancer in male carriers up to approx. 1% | in each carrier, prophylactic, bilateral adnexectomy is recommended, optimally at the age of 35–40 years, after completion of procreation plans |
| | | - breast cancer ≤ 50 years of age | | - risk of developing prostate cancer in carriers up to approx. 8.5% | carriers diagnosed with ovarian cancer are expected to respond well to platinum derivatives and PARP inhibitors |
| | | - triple negative TNBC breast cancer | | - risk of developing pancreatic cancer in carriers up to approx. 3% | each carrier should perform monthly self-palpation of the breasts |
| | | - ipsilateral and/or contralateral breast cancer | | | each carrier is recommended to breastfeed for a long time and to abandon/limit hormone replacement therapy (HRT) |
| | | - male breast cancer | | | each carrier is recommended to have a mammogram every 6 months (the age of beginning the tests depends on the family and clinical assessment, but should not be later that 25 years of age): MRI alternating with ultrasound (up to 30 years of age) or mammography (after 30 years of age) |
| | | - breast cancer in an Ashkenazi woman | | | in carriers who developed breast cancer, breast conserving surgery should be abandoned in favor of mastectomy, possibly with prophylactic contralateral mastectomy, ideally with simultaneous reconstruction |
| | | - two breast cancers among first/second/third degree relatives | | | each female carrier may consider a prophylactic bilateral mastectomy, optimally with simultaneous reconstruction |
| | | - three breast cancers among first/second/third degree relatives, regardless of age | | - a discreetly increased risk of developing melanoma (of the skin and/or eyeball) | chemoprevention with tamoxifen may be considered in any carrier |
| | | - pancreatic cancer and/or prostate cancer of Gleason score ≥ 7 and diagnosed breast cancer and/or ovarian cancer | | | in carriers who have developed triple-negative or luminal type breast cancer that progresses despite anti-estrogen therapy, PARP inhibitors (olaparib or talazaparib) should be considered as the next-line treatment (after anthracycline and taxanes) |
| | | | | | |
| Hereditary cancer syndrome | Genes in which germline mutations are present | Indications for genetic testing | Risk of ovarian cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|---------------------------|---------------------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|-----------------|
| hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) [8, 18, 22] | MLH1, MSH2, MSH6, EPCAM, PMS2 | a) in each case of colorectal cancer, the following tests should be performed: IHC studies to analyse expression of MLH1, MSH2, MSH6, and PMS2 proteins and/or microsatellite instability (MSI) on tumour cells; and a genetic test (sequencing and evaluation of large gene rearrangements associated with HNPCC) only in cases of abnormal IHC and/or MSI results | - risk of developing ovarian cancer up to approx. 20% | - risk of developing colorectal cancer up to approx. 74% | each male carrier should conduct regular breast self-examination, and from 30–35 years of age annual medical palpation of the breast is recommended (especially in carriers of the BRCA2 mutation) |
|                          |                                             | b) in cases where tumour cells and/or the person diagnosed with colorectal cancer are unavailable for testing, a genetic test (sequencing and evaluation of large gene rearrangements associated with HNPCC) should be performed, if at least Bethesda criteria are met: | - the patient was diagnosed with breast cancer before the age of 50 or ovarian cancer at any age, and in addition first and/or second grade relatives were diagnosed with male breast cancer and/or ovarian cancer | - risk of developing endometrial cancer up to approx. 5.4% | - annual colonoscopy is recommended for each carrier |
|                          |                                             | c) in families with identified specific BRCA1/2 mutation, hereditary mutation should be verified in the carrier’s family, above all first-degree relatives if a specific BRCA1/2 mutation is identified in DNA from tumor cells (tDNA), its presence should be analysed on DNA isolated from outside the tumor cells (blood, saliva, oral swab, skin biopsy specimen) to assess the nature of the mutation (somatic, i.e. non-hereditary or germline, i.e. hereditary) | - risk of developing gastric cancer up to approx. 18% | - risk of developing small intestinal cancer up to approx. 12% | - starting from 20–25 years of age in carriers of the MLH1 and MSH2 mutations |
|                          |                                             |                                  | - risk of developing prostate cancer up to approx. 30% | - risk of developing biliary duct cancer up to approx. 6% | - starting from 30–35 years of age in carriers of the MSH6, PMS2 and EPCAM mutations |
|                          |                                             |                                  | - risk of developing urinary tract (urothelial) cancer up to approx. 2.9% | - risk of developing a CNS tumor (so-called Turcot's syndrome) up to approx. 6% | in the case of diagnosed colorectal cancer, subtotal colectomy is recommended followed by endoscopic examinations of the preserved part of the large intestine at least every 2 years in each case from 30–35 years of age gastroduodenoscopy every 1–3 years should be considered |
|                          |                                             |                                  | - risk of developing a CNS tumor (so-called Turcot's syndrome) up to approx. 6% | - additionally, in carriers of the MLH1 or MSH2 mutation: | in each female carrier from 30–35 years of age annual TV-USG with endometrial biopsy is recommended (unless a hysterectomy has been previously performed) and further an annual evaluation of serum CA-12.5 concentration |
|                          |                                             |                                  | • increased risk of developing prostate cancer to approx. 30% | - increased risk of developing breast cancer to approx. 19% | each female carrier may consider prophylactic bilateral adnexectomy with hysterectomy after the completion of procreation plans (optimally around 35–40 years of age) |
|                          |                                             |                                  | • increased risk of developing breast cancer to approx. 19% | - increased risk of developing pancreatic cancer to approx. 9% | - annual neurological examination is recommended for each carrier |
|                          |                                             |                                  | • increased risk of developing sebaceous gland tumor (called Muir-Torre syndrome) to approx. 9% | - increased risk of developing sebaceous gland tumor (called Muir-Torre syndrome) to approx. 9% | |
| Hereditary cancer syndrome | Genes in which germline mutations are present | Indications for genetic testing | Risk of ovarian cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|---------------------------|---------------------------------------------|-------------------------------|-----------------------------------------------|------------------------------------------------|-----------------|
| Hereditary cancer syndrome | Genes in which germline mutations are present | Indications for genetic testing | Risk of ovarian cancer in carriers of the mutation | Other neoplasms in the spectrum of increased risk and associated symptoms | Recommendations |
|RAD51 germline mutations [23]| RAD51C RAD51D | – moderately increased risk of developing ovarian cancer: • for RAD51C OR mutation approx. 5% • for mutation RAD51D OR approx. 7% | – currently, there are no sufficient data concerning increased risk of development of other cancers | – each carrier may consider prophylactic bilateral adnexectomy after the age of 45 |

**Notes:**
1. ESMO – European Society for Medical Oncology
2. National Cancer Control Programme of the Ministry of Health
prophylaxis and therapy for carriers of germline mutations associated with hereditary cancer syndromes with ovarian cancer in their spectrum. As in the case of hereditary breast cancers, most hereditary ovarian cancers are associated with carrying germline BRCA1 or BRCA2 gene mutation, which account for the hereditary breast and ovarian cancer syndrome. However, there is also high risk of development of the ovarian cancer associated with mutations of MLH1, MSH2, MSH6, EPCAM, PMS2 genes, responsible for the hereditary non-polyposis colorectal cancer (HNPCC) or germline mutations in BRIP1, RAD51C or RAD51D genes (tab. III) [8, 21].

Currently, in patients with ovarian cancer, due to the growing importance of PARP inhibitors in therapy, it is recommended to start molecular diagnostics with sequencing of the BRCA1 and BRCA2 genes on tDNA, which can be isolated from both postoperative and biopsy material as well as from a tissue block. The results of the sequencing are then subjected to bioinformatic processing and thorough analysis in order to assess the clinical significance of the identified variants. Presence of BRCA1 or BRCA2 mutation (variations of class 5 and 4) in tDNA is a good predictive marker, which indicates probably high effectiveness of PARP inhibitors in therapy. Additionally, identification of BRCA1 or BRCA2 mutation in tDNA requires verification of the nature of the detected change (germline mutation which is hereditary or somatic mutation which is non-hereditary) through analysis of its occurrence in DNA isolated from cells outside the neoplasm. Interpretation of VUS variants (class 3, variants of unknown clinical significance) remains a challenge, both in terms of doubtful predictive value with respect to PARP inhibitors, and unknown effect of germline VUS on neoplasia risk.

Nevertheless, apart from patients with identified mutation in tDNA, genetic counselling should cover patients with no identified mutation in tDNA and those who did not have molecular testing on tDNA performed. Each patient with ovarian cancer referred for genetic counselling has their history and clinical analysis examined and differential diagnostics is performed considering hereditary breast-ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC aka Lynch syndrome). On the other hand, patients who did not have BRCA1 and BRCA2 genes sequenced in tDNA, are referred to genetic testing of constitutive genome for 5 founder mutations of BRCA1 gene. In the case of patients with family history, the testing is then expanded to include BRCA1 and BRCA2 gene sequencing. And only this is a basis for individual prophylactic and therapeutic recommendations (tab. III). In ovarian cancer patients, especially with family history of cancer who did not have mutations identified in BRCA1 and BRCA2 gene sequencing, broad-panel, commercial NGS testing may be considered, as it allows for sequencing many genes associated with many hereditary cancer syndromes within a single test. However, each genetic test has its limitations and if no mutation is found within the tested range, it does not unequivocally exclude the suspected hereditary cancer syndrome. Therefore, the final recommendations should be formulated based on a comprehensive analysis considering molecular testing results, as well as family and clinical assessment.

After diagnosis of a germline mutation, the patient should be informed of the risk of the mutation in the family. It is also necessary to provide genetic counselling not only to patients with inherited ovarian cancer, but to selected members of their families, too. Individualisation of medical recommendations applies to all mutation carriers (including those diagnosed with another cancer from the spectrum of a given cancer syndrome, as well as those without cancer diagnosis), and also families with cancer in which no causative mutation was detected.

Detailed characteristics of the most frequent hereditary cancer syndromes of spectrum including ovarian cancer, and therapeutic and prophylactic recommendations for mutation carriers considering ESMO guidelines and modules I and II of the NP2ChN Programme are shown in table III.

**Conclusion**

Personalised medicine is increasingly applied in prophylaxis and treatment of breast and ovarian cancers. Application of individually tailored therapies based on immunochemical and molecular markers increases the patients’ chances to avoid adverse effects, to prolong survival and progression-free survival.

Increasing access to molecular broad-panel and whole-genome testing allows identification of individual pathomechanisms that lead to neoplastic transformation within the tumour as well as to metastases, and this knowledge gives hope for application of potentially effective molecularly targeted therapies. Also, identification of patients with hereditary breast cancer and/or hereditary ovarian cancer enables development of individualised prophylactic and therapeutic recommendations for the patients, and for members of their families, too. However, this approach to diagnosing breast or ovarian cancer requires comprehensive assessment of the patient and multi-specialist, coordinated care by oncologist, surgeon, gynaecologist, geneticist, pathologist and laboratory diagnostician.

**Conflict of interest:** none declared

Anna Doraczyńska-Kowalik

Wrocław Medical University 
Department of Genetics
ul. K. Marcinkowskiego 1 
50-368 Wrocław 
e-mail: a.dor.kow@gmail.com

Received and accepted: 15 Aug 2020

**References**

1. Sąsiadek M, Łaczmańska I, Maciejczyk A, et al. Fundamentals of personalised medicine in genetic testing-based oncology. NOWOTWORY J Oncol. 2020; 70(4): 144–149, doi: 10.5603/njo.2020.0029.
2. Cardoso F, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(8): 1194–1220, doi: 10.1093/annonc/mdz173, indexed in PubMed: 3161190.

3. Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017; 75: 284–298, doi: 10.1016/j.ejca.2017.01.017, indexed in PubMed: 28259011.

4. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4th). Ann Oncol. 2018; 29(8): 1634–1657, doi: 10.1093/annonc/mdy192, indexed in PubMed: 30032243.

5. André F, Ciruelos E, Rubovszky G, et al. SOLAR-1 Study Group. Alpelisib for Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20): 1929–1940, doi: 10.1056/NEJMoa1813904, indexed in PubMed: 31091374.

6. Low SK, Zembitu H, Nakamura Y. Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Sci. 2018; 109(3): 497–506, doi: 10.1111/cas.13463, indexed in PubMed: 29215763.

7. Ross JS, Gay LM. Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer. Pathology, 2017; 49(2): 120–132, doi: 10.1016/j.pathol.2016.11.005, indexed in PubMed: 28634454.

8. Paluch-Shimon S, Cardoso F, Sessa C, et al. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016; 27(suppl 5): v103–v110, doi: 10.1093/annonc/mdw327, indexed in PubMed: 27664246.

9. Tung N, Lin NU, Kidd J, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Genomic Series of Patients With Breast Cancer. J Clin Oncol. 2016; 34(13): 1460–1468, doi: 10.1200/JCO.2015.65.0747, indexed in PubMed: 26976419.

10. Kowalik A, Siodek M, Kopczyński J, et al. BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study. PLoS One. 2018; 13(7): e0201086, doi: 10.1371/journal.pone.0201086, indexed in PubMed: 30040829.

11. Petruccelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al. ed. GeneReviews® [Internet]. University of Washington, Seattle 1993-2020.

12. Li MM, Datto M, Duncanavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017; 19(1): 4–23, doi: 10.1016/j.jmoldx.2016.10.002, indexed in PubMed: 27993330.

13. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014; 371(6): 497–506, doi: 10.1056/NEJMoa1400382, indexed in PubMed: 25099575.

14. Schneider K, Zelley K, Nichols KE, et al. Li-Fraumeni Syndrome. 1999 Jan 19 [Updated 2019 Nov 21]. In: Adam MP, Ardinger HH, Pagon RA, et al. ed. GeneReviews® [Internet]. University of Washington, Seattle 1993-2020.

15. Eng C. PTEN Hamartoma Tumor Syndrome. 2001 Nov 29 [Updated 2016 Jun 2]. In: Adam MP, Ardinger HH, Pagon RA, et al. ed. GeneReviews® [Internet]. University of Washington, Seattle 1993-2020.

16. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005; 97(11): 813–822, doi: 10.1093/jnci/dji141, indexed in PubMed: 15928302.

17. Kaurah P, Huntsman DG. Hereditary Diffuse Gastric Cancer. 2002 Nov 4 [Updated 2018 Mar 22]. In: Adam MP, Ardinger HH, Pagon RA, et al. ed. GeneReviews® [Internet]. University of Washington, Seattle 1993-2020.

18. Stepananov N, Moreira L, Carneiro F, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(10): 1558–1571, doi: 10.1093/annonc/mdz233, indexed in PubMed: 31378807.

19. McGarrity TJ, Amos CI, Baker MJ, Peutz-Jeghers Syndrome. 2001 Feb 23 [Updated 2016 Jul 14]. In: Adam MP, Ardinger HH, Pagon RA, et al. ed. GeneReviews® [Internet]. University of Washington, Seattle 1993-2020.

20. Ledermann JA, Raja FA, Fotopoulou C, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi24–vi32, doi: 10.1093/annonc/mdt333, indexed in PubMed: 24078660.

21. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108(44): 18032–18037, doi: 10.1073/pnas.1105251208, indexed in PubMed: 22006311.

22. Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [Updated 2018 Apr 12]. In: Adam MP, Ardinger HH, Pagon RA, et al. ed. GeneReviews® [Internet]. University of Washington, Seattle 1993-2020.

23. Suszyńska M, Ratańska M, Kołodziew P. BRIP1, RADS1/C, and RADS1D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res. 2020; 13(1): 50, doi: 10.1186/s13048-020-00654-3, indexed in PubMed: 32359370.